Quick Answer
Tarsus Pharmaceuticals, Inc. reported Total Revenue of $451.36 million for the year ending 2025.
- Tarsus Pharmaceuticals, Inc. showed an increase of +146.7% in Total Revenue from 2024 to 2025.
- This data is from Tarsus Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $0.00 | Q2 2020: $0.00 | Q3 2020: $0.00 | Q1 2021: $33.43 million | Q2 2021: $22.02 million | Q3 2021: $1.24 million | Q1 2022: $539.0 thousand | Q2 2022: $15.28 million | Q3 2022: $0.00 | Q1 2023: $2.50 million | Q2 2023: $0.00 | Q3 2023: $1.87 million | Q1 2024: $27.61 million | Q2 2024: $40.81 million | Q3 2024: $48.12 million | Q1 2025: $78.34 million | Q2 2025: $102.66 million | Q3 2025: $118.70 million.
- Historical annual values: Fiscal year 2025: $451.36 million | Fiscal year 2024: $182.95 million | Fiscal year 2023: $17.45 million | Fiscal year 2022: $25.82 million | Fiscal year 2021: $57.03 million | Fiscal year 2020: $0.00.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: